Remission, low disease activity and relapse in patients with juvenile-, adult- and late-onset SLE
- 1 September 2026
- journal article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Abstract
Objective: To evaluate remission, low disease activity and relapse in patients with SLE according to age at disease onset. Methods: We conducted a retrospective cohort study including patients classified with SLE according to the 2019 EULAR/ACR criteria. Patients were grouped by age at onset as juvenile-onset SLE (jSLE, <18 years), adult-onset SLE (aSLE, 18–49 years) and late-onset SLE (lSLE, ≥50 years). Patients with other autoimmune diseases were excluded, except antiphospholipid syndrome and Sjögren. Clinical data and outcomes were obtained from medical records. Remission was defined according to DORIS, low disease activity according to LLDAS and relapse according to the SELENA-SLEDAI Flare Index. Results: A total of 289 patients were included: 96 with jSLE, 96 with aSLE and 97 with lSLE; 90.5% female. At diagnosis, jSLE patients had higher disease activity. Neuropsychiatric manifestations were more frequent in jSLE, while mucocutaneous involvement and nephritis predominated in aSLE. Remission and LLDAS were achieved more frequently in lSLE; concordantly, lSLE independently predicted remission and LLDAS (HR 2.8; 95% CI 1.9–4.0 and HR 2.4; 95% CI 1.7–3.4; P < 0.001). Relapses were more frequent in jSLE (87.5%) compared with aSLE (66.7%) and lSLE (24.7%; P < 0.001). Factors associated with relapse were jSLE (HR 2.1; 95% CI 1.5–2.9; P = 0.008) and constitutional manifestations at onset (HR 1.6; 95% CI 1.2–2.4; P = 0.048). Mortality was higher in lSLE, with infections as the main cause. Conclusion: jSLE was associated with higher relapse rates, whereas late-onset SLE was independently associated with achieving remission and LLDAS.Keywords
This publication has 38 references indexed in Scilit:
- Framework for implementing treat-to-target in systemic lupus erythematosus routine clinical care: consensus statements from an international task forceAutoimmunity Reviews, 2025
- Clinical patterns of disease: From early systemic lupus erythematosus to late-onset diseaseBest Practice & Research Clinical Rheumatology, 2023
- The 2023 ACR/EULAR Antiphospholipid Syndrome Classification CriteriaArthritis & Rheumatology, 2023
- Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long‐Term Clinical Outcomes: A Five‐Year Prospective StudyArthritis & Rheumatology, 2022
- Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosusThe Lancet Child & Adolescent Health, 2022
- Late-onset systemic lupus erythematosus: characteristics and outcome in comparison to juvenile- and adult-onset patients—a multicenter retrospective cohortClinical Rheumatology, 2019
- 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus ErythematosusArthritis & Rheumatology, 2019
- Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosusClinical Rheumatology, 2016
- Lessons from SLE: children are not little adultsNature Reviews Rheumatology, 2012
- The Systemic Lupus Erythematosus Responder Index (SRI); A new SLE disease activity assessmentAutoimmunity Reviews, 2012